Darwin Global Health Care

Analytical Models

Sat Aug 02 21:11:06 UTC 2025

Here is a Model Score report:

	Model Score	MA Fcst	Signals	Neural Fcst	GANN Fcst	Boll Fcst
EssilorLuxottica SA (EL)	+25	+6	+17	+1	+1	0
Prestige Consumer Healthcare Inc (PBH)	+23	+6	+11	+1	+1	+4
Haleon PLC (HLN)	+17	+6	+7	+1	+1	+2
Pro Medicus Ltd (PME)	+16	+6	+8	+1	-1	+2
Nanosonics Ltd (NAN)	+15	+6	+5	-1	+1	+4
Healthequity Inc (HQY)	+15	+6	+8	-1	-1	+3
Argenica Therapeutics Ltd (AGN)	+13	+6	+1	+1	+1	+4
Sanofi SA (SAN)	+13	+6	+6	0	+1	0
Hims & Hers Health Inc (HIMS)	+13	+6	+3	+1	+1	+2
Telix Pharmaceuticals Ltd (TLX)	+11	+6	+3	-1	-1	+4
Sigma Healthcare Ltd (SIG)	+11	+6	+3	+1	0	+1
Regis Healthcare Ltd (REG)	+11	+6	+1	+1	+1	+2
Concentra Group Holdings Parent Inc (CON)	+11	+6	0	+1	+1	+3
Bioventus Inc (BVS)	+10	+6	0	+1	-1	+4
Vertex Pharmaceuticals Inc (VRTX)	+10	+6	+6	-1	-1	0
ConvaTec Group PLC (CTEC)	+10	+6	+3	0	0	+1
Uniphar PLC (UPR)	+10	+6	+1	0	0	+3
Sagimet Biosciences Inc (SGMT)	+10	+6	0	+1	-1	+4
Mesoblast Ltd (MSB)	+9	+6	-1	+1	-1	+4
Intuitive Surgical Inc (ISRG)	+9	+6	+1	0	-1	+3
Koninklijke Philips NV (PHIA)	+9	+6	0	+1	-1	+3
Alcon AG (ALC)	+9	+6	+2	+1	-1	+1
Race Oncology Ltd (RAC)	+8	+6	-1	+1	-1	+3
Integral Diagnostics Ltd (IDX)	+8	+6	-1	-1	+1	+3
AstraZeneca PLC (AZN)	+8	+6	0	+1	-1	+2
Sonova Holding AG (SOON)	+8	+6	+2	-1	-1	+2
Merck KGaA (MRK)	+8	+6	0	+1	+1	0
CVS Health Corp (CVS)	+8	+6	0	+1	+1	0
Klotho Neurosciences Inc (KLTO)	+8	+4	0	-1	+1	+4
Physiomics PLC (PYC)	+7	+6	-5	+1	+1	+4
Dermapharm Holding SE (DMP)	+7	+6	-3	+1	-1	+4
CSL Ltd (CSL)	+7	+6	-1	+1	-1	+2
Oragenics Inc (OGEN)	+7	+2	+3	-1	-1	+4
Ansell Ltd (ANN)	+6	+6	0	0	0	0
Humana Inc (HUM)	+6	+6	0	-1	-1	+2
Amgen Inc (AMGN)	+6	+6	0	+1	-1	0
GSK plc (GSK)	+6	+6	+2	-1	-1	0
Biomerieux SA (BIM)	+6	+6	-1	0	+1	0
Demant A/S (DEMANT)	+6	+6	-2	-1	+1	+2
ICON PLC (ICLR)	+6	+6	0	+1	-1	0
Aspen Pharmacare Holdings Ltd (APN)	+6	+6	-2	+1	+1	0
PYC Therapeutics Ltd (PYC)	+5	+6	-3	-1	+1	+2
Evotec SE (EVT)	+5	+4	-3	+1	-1	+4
Cochlear Ltd (COH)	+5	+6	0	0	-1	0
Coloplast A/S (COLO_B)	+5	+6	-3	+1	+1	0
Merck & Co Inc (MRK)	+5	+6	-1	+1	-1	0
Doximity Inc (DOCS)	+5	+6	+1	-1	+1	-2
Siemens Healthineers AG (SHL)	+4	+4	0	-1	+1	0
Resmed Inc (RMD)	+4	+6	-2	0	0	0
Polynovo Ltd (PNV)	+4	+6	-3	-1	-1	+3
Gilead Sciences Inc (GILD)	+4	+6	0	-1	-1	0
Novo Nordisk A/S (NOVO-B)	+4	+6	-2	-1	-1	+2
Anteotech Ltd (ADO)	+3	+6	-3	0	0	0
Lonza Group AG (LONN)	+3	+6	-1	-1	-1	0
Abivax SA (ABVX)	+3	+6	-5	-1	-1	+4
MoonLake Immunotherapeutics (MLTX)	+3	+6	+2	-1	0	-4
Alcidion Group Ltd (ALC)	+2	+6	-6	-1	+1	+2
Zealand Pharma A/S (ZEAL)	+2	+6	-10	+1	+1	+4
Johnson & Johnson (JNJ)	+2	+6	-2	-1	-1	0
Roche Holding AG (ROG)	+2	+4	0	-1	-1	0
Pharming Group NV (PHARM)	+2	+2	0	-1	+1	0
Roche Holding AG (RO)	+2	+4	0	-1	-1	0
Imugene Ltd (IMU)	+1	+4	-3	-1	-1	+2
Epigenomics AG (ECX)	+1	-2	+1	-1	+1	+2
Charles River Laboratories International Inc (CRL)	+1	+6	-7	+1	+1	0
Clearside Biomedical Inc (CLSD)	+1	-2	0	+1	-1	+3
Sonic Healthcare Ltd (SHL)	0	+6	-4	-1	-1	0
Medical Developments International Ltd (MVP)	0	+4	-3	0	-1	0
Regeneron Pharmaceuticals Inc (REGN)	0	0	-1	0	0	+1
Fresenius Medical Care AG (FME)	-1	0	0	-1	-1	+1
Pharvaris NV (PHVS)	-1	+6	-8	-1	-1	+3
Straumann Holding AG (STMN)	-1	+6	-4	-1	-1	-1
Lyra Therapeutics Inc (LYRA)	-1	+2	-1	+1	-1	-2
Healthcare Triangle Inc (HCTI)	-1	0	-2	-1	+1	+1
Imunon Inc (IMNN)	-1	+6	-5	+1	-1	-2
Shield Therapeutics PLC (STX)	-2	+2	-2	-1	-1	0
Opthea Ltd (OPT)	-2	-4	0	+1	+1	0
Hikma Pharmaceuticals PLC (HIK)	-3	-2	+1	-1	-1	0
Novartis AG (NOVN)	-3	-2	+1	-1	-1	0
Ecofibre Ltd (EOF)	-4	-6	0	0	-1	+3
Genmab A/S (GMAB)	-5	-2	-3	+1	-1	0
Emergent BioSolutions Inc (EBS)	-5	-2	-3	+1	+1	-2
60 Degrees Pharmaceuticals Inc (SXTP)	-5	-6	0	+1	+1	-1
Surgical Innovations Group PLC (SUN)	-6	-6	-4	+1	+1	+2
Illumina Inc (ILMN)	-6	+4	-12	+1	+1	0
BTC Health Ltd (BTC)	-6	-4	0	0	0	-2
Innate Pharma SA (IPH)	-7	-4	-1	+1	+1	-4
Angle PLC (AGL)	-8	-2	-1	-1	-1	-3
Mayne Pharma Group Ltd (MYX)	-8	-6	-1	+1	-1	-1
Incyte Corp (INCY)	-8	-6	0	-1	-1	0
Smith & Nephew PLC (SN.)	-8	-4	-2	-1	-1	0
Turnstone Biologics Corp (TSBX)	-8	-6	0	+1	+1	-4
Cardiol Therapeutics Inc (CRDL)	-8	-2	0	-1	-1	-4
Pacific Smiles Group Ltd (PSQ)	-9	-6	-1	+1	-1	-2
Ambu A/S (AMBU_B)	-9	+6	-17	+1	+1	0
Arecor Therapeutics PLC (AREC)	-9	-6	-5	0	-1	+3
Eyenovia Inc (EYEN)	-9	+2	-17	+1	+1	+4
Clinuvel Pharmaceuticals Ltd (CUV)	-10	+6	-17	+1	-1	+1
Traws Pharma Inc (TRAW)	-10	-6	0	+1	-1	-4
Agenus Inc (AGEN)	-10	-4	-11	+1	+1	+3
Paradigm Biopharmaceuticals Ltd (PAR)	-11	+6	-11	-1	-1	-4
Sartorius Stedim Biotech SA (DIM)	-11	+6	-22	+1	+1	+3
Advanced Medical Solutions Group PLC (AMS)	-11	-6	-5	0	0	0
Innovotech Inc (IOT)	-11	-2	-5	0	0	-4
Kiora Pharmaceuticals Inc (KPRX)	-11	-6	-5	+1	-1	0
Cellectar Biosciences Inc (CLRB)	-11	-6	-2	-1	+1	-3
Bluejay Diagnostics Inc (BJDX)	-11	-6	0	-1	-1	-3
Henry Schein Inc (HSIC)	-12	-2	-8	-1	-1	0
Plus Therapeutics Inc (PSTV)	-12	-6	0	-1	-1	-4
Conduit Pharmaceuticals Inc (CDT)	-12	-6	-2	0	-1	-3
Kronos Bio Inc (KRON)	-12	-6	-1	-1	-1	-3
Helius Medical Technologies Inc (HSDT)	-12	-6	-1	-1	-1	-3
PMGC Holdings Inc (ELAB)	-12	-6	0	-1	-1	-4
Healius Ltd (HLS)	-13	-4	-7	-1	-1	0
Bio-Techne Corp (TECH)	-13	+6	-20	-1	-1	+3
Geratherm Medical AG (GME)	-13	-6	-2	0	-1	-4
PolyPid Ltd (PYPD)	-14	-6	-4	0	0	-4
Starpharma Holdings Ltd (SPL)	-15	-6	-6	0	0	-3
Biogen Inc (BIIB)	-15	-6	-8	+1	+1	-3
Ramsay Health Care Ltd (RHC)	-16	-6	-8	-1	0	-1
InMed Pharmaceuticals Inc (INM)	-16	-6	-7	0	0	-3
Phio Pharmaceuticals Corp (PHIO)	-16	-6	-6	0	0	-4
DENTSPLY SIRONA Inc (XRAY)	-17	0	-17	0	+1	-1
BioMarin Pharmaceutical Inc (BMRN)	-17	-4	-7	-1	-1	-4
Revelation Biosciences Inc (REVB)	-17	-6	-5	-1	-1	-4
Athira Pharma Inc (ATHA)	-17	-6	-9	-1	-1	0
Tempest Therapeutics Inc (TPST)	-17	-6	-7	-1	-1	-2
Nuwellis Inc (NUWE)	-17	-6	-7	-1	+1	-4
Alzamend Neuro Inc (ALZN)	-18	-6	-9	+1	-1	-3
Cannara Biotech Inc (LOVE)	-18	-6	-12	0	0	0
GN Store Nord A/S (GN)	-20	+4	-21	+1	-1	-3
agilon health inc (AGL)	-21	-6	-10	0	-1	-4
Bavarian Nordic A/S (BAVA)	-21	+4	-20	-1	-1	-3
Sharps Technology Inc (STSS)	-22	-6	-12	+1	-1	-4
Cleanspace Holdings Ltd (CSX)	-33	-6	-27	+1	-1	0
GlycoMimetics Inc (GLYC)	-40	+6	-42	0	0	-4
NewGenIvf Group Ltd (NIVF)	0	0	0	0	0	0
Basel Medical Group Ltd (BMGL)	0	0	0	0	0	0

High Activity Screen

Sat Aug 02 20:28:08 UTC 2025

Here is a list of assets moving up or down on unusually high volume.

Asset		1 Day Return (%)	Vol Rel 20d
Sanofi SA (SAN)	Up on High Volume	+1.9	2.1x
BioMarin Pharmaceutical Inc (BMRN)	Up on High Volume	+0.5	2.1x
Biogen Inc (BIIB)	Up on High Volume	+3.1	2.0x
Innovotech Inc (IOT)	Up on High Volume	+4.2	1.9x
Regeneron Pharmaceuticals Inc (REGN)	Up on High Volume	+2.5	1.8x
Resmed Inc (RMD)	Up on High Volume	+2.7	1.7x
MoonLake Immunotherapeutics (MLTX)	Up on High Volume	+4.9	1.7x
Vertex Pharmaceuticals Inc (VRTX)	Up on High Volume	+1.2	1.6x
Regis Healthcare Ltd (REG)	Up on High Volume	+1.0	1.5x
Intuitive Surgical Inc (ISRG)	Up on High Volume	+0.4	1.4x
Amgen Inc (AMGN)	Up on High Volume	+0.6	1.3x
Healthcare Triangle Inc (HCTI)	Down on High Volume	-38.9	19.3x
Novo Nordisk A/S (NOVO-B)	Down on High Volume	-1.8	3.2x
Pharming Group NV (PHARM)	Down on High Volume	-4.1	2.8x
Telix Pharmaceuticals Ltd (TLX)	Down on High Volume	-4.3	2.2x
DENTSPLY SIRONA Inc (XRAY)	Down on High Volume	-0.1	2.0x
Dermapharm Holding SE (DMP)	Down on High Volume	-0.9	2.0x
Illumina Inc (ILMN)	Down on High Volume	-7.8	2.0x
Demant A/S (DEMANT)	Down on High Volume	-1.7	1.9x
Ambu A/S (AMBU_B)	Down on High Volume	-4.5	1.9x
Imugene Ltd (IMU)	Down on High Volume	-7.4	1.8x
Healthequity Inc (HQY)	Down on High Volume	-6.1	1.6x
Aspen Pharmacare Holdings Ltd (APN)	Down on High Volume	-1.4	1.6x
Zealand Pharma A/S (ZEAL)	Down on High Volume	-4.7	1.5x
EssilorLuxottica SA (EL)	Down on High Volume	-2.0	1.4x
Siemens Healthineers AG (SHL)	Down on High Volume	-1.8	1.4x
Alcon AG (ALC)	Down on High Volume	-1.5	1.4x
CSL Ltd (CSL)	Down on High Volume	-2.5	1.4x
Emergent BioSolutions Inc (EBS)	Down on High Volume	-4.3	1.3x
Merck KGaA (MRK)	Down on High Volume	-2.9	1.3x

Regeneron Pharmaceuticals Inc (Score +6)

Sat Aug 02 20:26:23 UTC 2025

US Stocks: Regeneron Pharmaceuticals Inc has an overall darwin score of +6

The score is composed from the following sections:

• +5 Price
• 0 Sentiment
• +3 Fundamentals
• -2 Flow
• 0 Models

https://dev.darwinknows.com/assets/REGN.XNGS
#DarwinKnows #RegeneronPharmaceuticals #REGN $REGN

Innate Pharma SA (Valuation - Very Expensive)

Sat Aug 02 20:26:12 UTC 2025

Innate Pharma SA has the worst Darwin score in France. Innate Pharma SA has an overall darwin score of -15

The valuation ratios for Innate Pharma SA present a troubling picture. The Enterprise Value to EBITDA ratio is -9.783, which is significantly worse than the peer average of -0.396, indicating that the market is valuing the company unfavorably compared to its earnings potential. The Price to Sales ratio stands at 6.989, while the peer average is 22.834, suggesting that the stock is overvalued relative to its sales. Furthermore, the earnings per share is negative at -0.610, contrasting sharply with the peer average of 0.345. Given these metrics, the company appears to be 'very expensive' as it struggles to generate profits and maintain a favorable valuation compared to its peers.

https://dev.darwinknows.com/assets/IPH.XPAR
#DarwinKnows #InnatePharma #IPH $IPH.FR

GlycoMimetics Inc (Overall - Unfavourable)

Sat Aug 02 20:26:11 UTC 2025

GlycoMimetics Inc has the worst Darwin score in United States. GlycoMimetics Inc has an overall score of -64

The overall assessment of GlycoMimetics Inc is "unfavourable." The combination of unhealthy operational metrics, very expensive valuation ratios, neutral price sentiment, and positive model forecasts paints a concerning picture for potential investors. The negative earnings per share and profit margins indicate significant challenges in operational efficiency and profitability. While the positive outlook from the models suggests potential for price appreciation, the high valuation raises concerns about the sustainability of such growth. Investors should approach this asset with caution, as the risks appear to outweigh the potential rewards at this time.

https://dev.darwinknows.com/assets/GLYC.XNCM
#DarwinKnows #GlycoMimetics #GLYC $GLYC

Amgen Inc (Score +39)

Sat Aug 02 20:26:07 UTC 2025

US Large Caps: Amgen Inc has an overall darwin score of +39

The score is composed from the following sections:

• +29 Price
• 0 Sentiment
• +4 Fundamentals
• 0 Flow
• +6 Models

https://dev.darwinknows.com/assets/AMGN.XNGS
#DarwinKnows #Amgen #AMGN $AMGN

Athira Pharma Inc (Score -4)

Sat Aug 02 20:26:04 UTC 2025

US Stocks: Athira Pharma Inc has a total score of -4

The score is composed from the following sections:

• +21 Price
• 0 Sentiment
• +1 Fundamentals
• -9 Flow
• -17 Models

https://dev.darwinknows.com/assets/ATHA.XNCM
#DarwinKnows #AthiraPharma #ATHA $ATHA

Market Cycle Analysis

Sat Aug 02 19:17:05 UTC 2025

The median 1m Return(%) is -1.6 and the median 12m Return(%) is -12.7. The analysis of the relative performance of these assets is as follows in the table below:

Asset	Market Cycle	Score	12m Return (%)	1m Return(%)
Abivax SA (ABVX)	Leading	+11	+400.8	+770.6
Alcidion Group Ltd (ALC)	Leading	+17	+103.4	+20.0
Alcon AG (ALC)	Leading	-16	-10.4	+3.0
Amgen Inc (AMGN)	Leading	+39	-5.7	-0.5
AstraZeneca PLC (AZN)	Leading	-5	-6.3	+7.4
Bavarian Nordic A/S (BAVA)	Leading	-11	+25.9	+36.1
Biomerieux SA (BIM)	Leading	+31	+32.3	+4.3
Cannara Biotech Inc (LOVE)	Leading	-1	+213.3	+21.3
Cleanspace Holdings Ltd (CSX)	Leading	-12	+146.8	+56.1
Cochlear Ltd (COH)	Leading	+32	-5.0	+3.8
EssilorLuxottica SA (EL)	Leading	+29	+34.6	+9.4
Gilead Sciences Inc (GILD)	Leading	+29	+67.0	+1.3
GSK plc (GSK)	Leading	+14	-2.8	-0.6
Hims & Hers Health Inc (HIMS)	Leading	+8	+197.1	+30.4
Incyte Corp (INCY)	Leading	0	+21.4	+10.4
Innate Pharma SA (IPH)	Leading	-15	-8.1	+21.6
Integral Diagnostics Ltd (IDX)	Leading	+21	+8.1	+6.3
Johnson & Johnson (JNJ)	Leading	+35	+15.4	+7.3
Koninklijke Philips NV (PHIA)	Leading	+6	-1.2	+12.6
Kronos Bio Inc (KRON)	Leading	+8	+10.7	+31.1
Lonza Group AG (LONN)	Leading	+9	+14.0	+2.7
Mayne Pharma Group Ltd (MYX)	Leading	-2	+14.2	0
Mesoblast Ltd (MSB)	Leading	-8	+99.2	+44.2
MoonLake Immunotherapeutics (MLTX)	Leading	+15	+13.4	+8.2
Nanosonics Ltd (NAN)	Leading	+7	+20.2	+0.5
Opthea Ltd (OPT)	Leading	-13	+60.0	0
Pharming Group NV (PHARM)	Leading	+7	+17.2	+3.9
Pharvaris NV (PHVS)	Leading	+22	+9.6	+7.5
Pro Medicus Ltd (PME)	Leading	+36	+133.4	+2.0
Regis Healthcare Ltd (REG)	Leading	+21	+96.5	+12.4
Resmed Inc (RMD)	Leading	+20	+41.0	+8.7
Roche Holding AG (RO)	Leading	-3	+3.4	-0.7
Roche Holding AG (ROG)	Leading	-3	+8.6	-0.2
Sagimet Biosciences Inc (SGMT)	Leading	+27	+152.3	0
Shield Therapeutics PLC (STX)	Leading	+15	+181.3	+57.9
Siemens Healthineers AG (SHL)	Leading	-2	-12.5	-0.6
Smith & Nephew PLC (SN.)	Leading	+21	+11.7	+4.0
Sonic Healthcare Ltd (SHL)	Leading	+29	+8.3	+0.7
Starpharma Holdings Ltd (SPL)	Leading	-11	-4.0	+5.5
Surgical Innovations Group PLC (SUN)	Leading	-2	+64.7	0
Uniphar PLC (UPR)	Leading	+20	+55.0	+5.2
Vertex Pharmaceuticals Inc (VRTX)	Leading	+7	-6.1	+0.5
Anteotech Ltd (ADO)	Rising	+15	-14.3	+38.5
Arecor Therapeutics PLC (AREC)	Rising	+4	-44.1	+28.1
Athira Pharma Inc (ATHA)	Rising	-4	-88.7	+8.9
Bio-Techne Corp (TECH)	Rising	-10	-27.8	+3.3
Biogen Inc (BIIB)	Rising	-8	-44.3	-0.7
BioMarin Pharmaceutical Inc (BMRN)	Rising	-17	-30.7	+1.1
Charles River Laboratories International Inc (CRL)	Rising	+8	-20.9	+6.2
Clinuvel Pharmaceuticals Ltd (CUV)	Rising	-19	-19.2	+22.3
Coloplast A/S (COLO_B)	Rising	-5	-30.0	-1.6
CSL Ltd (CSL)	Rising	+12	-12.9	+8.8
Ecofibre Ltd (EOF)	Rising	-9	-48.7	0
Eyenovia Inc (EYEN)	Rising	+15	-74.0	+590.4
Genmab A/S (GMAB)	Rising	-9	-21.4	+6.8
Geratherm Medical AG (GME)	Rising	-17	-17.0	+2.1
Healius Ltd (HLS)	Rising	-28	-29.8	+3.4
Humana Inc (HUM)	Rising	-1	-34.0	+3.2
ICON PLC (ICLR)	Rising	+24	-50.2	+10.9
Nuwellis Inc (NUWE)	Rising	-19	-94.8	+10.4
Physiomics PLC (PYC)	Rising	-3	-36.6	+10.8
Plus Therapeutics Inc (PSTV)	Rising	-8	-67.9	+96.7
Polynovo Ltd (PNV)	Rising	-2	-47.9	+1.2
Race Oncology Ltd (RAC)	Rising	0	-37.3	+1.3
Regeneron Pharmaceuticals Inc (REGN)	Rising	+6	-48.1	+2.1
Revelation Biosciences Inc (REVB)	Rising	-8	-97.2	+7.0
Tempest Therapeutics Inc (TPST)	Rising	-16	-73.4	+5.0
Traws Pharma Inc (TRAW)	Rising	-22	-83.2	+0.7
Advanced Medical Solutions Group PLC (AMS)	Fading	-15	-11.8	-2.7
Ansell Ltd (ANN)	Fading	+26	+20.0	-4.3
Bioventus Inc (BVS)	Fading	+15	-6.1	-12.0
BTC Health Ltd (BTC)	Fading	+27	+62.5	-4.4
ConvaTec Group PLC (CTEC)	Fading	+15	-4.1	-12.6
CVS Health Corp (CVS)	Fading	+31	+13.5	-6.3
Dermapharm Holding SE (DMP)	Fading	+17	-5.2	-5.7
Doximity Inc (DOCS)	Fading	+17	+111.6	-7.1
Epigenomics AG (ECX)	Fading	+7	+34.1	-45.2
Fresenius Medical Care AG (FME)	Fading	+5	+23.4	-9.4
Haleon PLC (HLN)	Fading	+21	+12.1	-3.3
Healthequity Inc (HQY)	Fading	+18	+20.2	-10.9
Henry Schein Inc (HSIC)	Fading	-3	+4.4	-9.0
Hikma Pharmaceuticals PLC (HIK)	Fading	-1	+8.0	-2.0
Innovotech Inc (IOT)	Fading	+12	+78.6	-16.7
Intuitive Surgical Inc (ISRG)	Fading	+20	+8.9	-11.3
Medical Developments International Ltd (MVP)	Fading	+19	+16.8	-8.6
Novartis AG (NOVN)	Fading	+26	+0.5	-2.7
Pacific Smiles Group Ltd (PSQ)	Fading	-6	-8.7	-1.8
Paradigm Biopharmaceuticals Ltd (PAR)	Fading	+13	+15.0	-25.8
Prestige Consumer Healthcare Inc (PBH)	Fading	+4	+5.0	-7.8
PYC Therapeutics Ltd (PYC)	Fading	+27	-2.7	-5.5
Sanofi SA (SAN)	Fading	+4	-9.1	-3.5
Sartorius Stedim Biotech SA (DIM)	Fading	-8	-1.8	-15.8
Sigma Healthcare Ltd (SIG)	Fading	+16	+112.6	-5.0
Telix Pharmaceuticals Ltd (TLX)	Fading	+1	+1.1	-16.7
60 Degrees Pharmaceuticals Inc (SXTP)	Lagging	-2	-91.0	-44.1
Agenus Inc (AGEN)	Lagging	+28	-65.2	-11.7
agilon health inc (AGL)	Lagging	-27	-72.4	-30.0
Alzamend Neuro Inc (ALZN)	Lagging	-21	-94.3	-25.2
Ambu A/S (AMBU_B)	Lagging	-25	-30.0	-7.5
Angle PLC (AGL)	Lagging	-29	-59.3	-4.0
Argenica Therapeutics Ltd (AGN)	Lagging	+7	-23.4	-2.9
Aspen Pharmacare Holdings Ltd (APN)	Lagging	+1	-49.9	-2.5
Bluejay Diagnostics Inc (BJDX)	Lagging	-8	-95.0	-8.0
Cardiol Therapeutics Inc (CRDL)	Lagging	+13	-34.1	-7.7
Cellectar Biosciences Inc (CLRB)	Lagging	-19	-93.6	-1.7
Clearside Biomedical Inc (CLSD)	Lagging	+13	-68.3	-52.7
Conduit Pharmaceuticals Inc (CDT)	Lagging	-10	-99.6	-38.4
Demant A/S (DEMANT)	Lagging	+12	-18.0	-8.1
DENTSPLY SIRONA Inc (XRAY)	Lagging	-6	-42.4	-14.2
Emergent BioSolutions Inc (EBS)	Lagging	+14	-43.1	-19.5
Evotec SE (EVT)	Lagging	+12	-19.7	-3.5
GlycoMimetics Inc (GLYC)	Lagging	-64	-44.4	-37.1
GN Store Nord A/S (GN)	Lagging	-19	-50.5	-8.9
Healthcare Triangle Inc (HCTI)	Lagging	+3	-96.0	-25.5
Helius Medical Technologies Inc (HSDT)	Lagging	-18	-99.0	-35.1
Illumina Inc (ILMN)	Lagging	+3	-19.8	-6.1
Imugene Ltd (IMU)	Lagging	-10	-86.6	-41.2
Imunon Inc (IMNN)	Lagging	-7	-60.4	-28.3
InMed Pharmaceuticals Inc (INM)	Lagging	-19	-56.9	-17.9
Kiora Pharmaceuticals Inc (KPRX)	Lagging	-14	-40.0	-10.9
Klotho Neurosciences Inc (KLTO)	Lagging	+26	-47.7	-19.3
Lyra Therapeutics Inc (LYRA)	Lagging	+4	-54.9	-26.9
Merck & Co Inc (MRK)	Lagging	+43	-36.4	-2.0
Merck KGaA (MRK)	Lagging	-2	-29.1	-3.7
NewGenIvf Group Ltd (NIVF)	Lagging	0	-99.8	-56.8
Novo Nordisk A/S (NOVO-B)	Lagging	0	-67.4	-29.5
Oragenics Inc (OGEN)	Lagging	+5	-96.3	-18.3
Phio Pharmaceuticals Corp (PHIO)	Lagging	+20	-60.1	-2.9
PMGC Holdings Inc (ELAB)	Lagging	-1	-99.7	-12.9
PolyPid Ltd (PYPD)	Lagging	+6	-16.2	-2.6
Ramsay Health Care Ltd (RHC)	Lagging	+3	-16.8	-3.3
Sharps Technology Inc (STSS)	Lagging	-2	-99.7	-16.7
Sonova Holding AG (SOON)	Lagging	+10	-17.0	-5.6
Straumann Holding AG (STMN)	Lagging	+5	-15.0	-6.6
Turnstone Biologics Corp (TSBX)	Lagging	+10	-86.0	-3.2
Zealand Pharma A/S (ZEAL)	Lagging	-7	-65.7	-12.7

Regeneron Pharmaceuticals Inc (Score +6)

Sat Aug 02 19:05:38 UTC 2025

US Stocks: Regeneron Pharmaceuticals Inc has an overall darwin score of +6

The score is composed from the following sections:

• +5 Price
• 0 Sentiment
• +3 Fundamentals
• -2 Flow
• 0 Models

https://dev.darwinknows.com/assets/REGN.XNGS
#DarwinKnows #RegeneronPharmaceuticals #REGN $REGN

Innate Pharma SA (Valuation - Very Expensive)

Sat Aug 02 19:05:28 UTC 2025

Innate Pharma SA has the worst Darwin score in France. Innate Pharma SA has an overall darwin score of -15

The valuation ratios for Innate Pharma SA present a troubling picture. The Enterprise Value to EBITDA ratio is -9.783, which is significantly worse than the peer average of -0.396, indicating that the market is valuing the company unfavorably compared to its earnings potential. The Price to Sales ratio stands at 6.989, while the peer average is 22.834, suggesting that the stock is overvalued relative to its sales. Furthermore, the earnings per share is negative at -0.610, contrasting sharply with the peer average of 0.345. Given these metrics, the company appears to be 'very expensive' as it struggles to generate profits and maintain a favorable valuation compared to its peers.

https://dev.darwinknows.com/assets/IPH.XPAR
#DarwinKnows #InnatePharma #IPH $IPH.FR

GlycoMimetics Inc (Overall - Unfavourable)

Sat Aug 02 19:05:26 UTC 2025

GlycoMimetics Inc has the worst Darwin score in United States. GlycoMimetics Inc has an overall score of -64

The overall assessment of GlycoMimetics Inc is "unfavourable." The combination of unhealthy operational metrics, very expensive valuation ratios, neutral price sentiment, and positive model forecasts paints a concerning picture for potential investors. The negative earnings per share and profit margins indicate significant challenges in operational efficiency and profitability. While the positive outlook from the models suggests potential for price appreciation, the high valuation raises concerns about the sustainability of such growth. Investors should approach this asset with caution, as the risks appear to outweigh the potential rewards at this time.

https://dev.darwinknows.com/assets/GLYC.XNCM
#DarwinKnows #GlycoMimetics #GLYC $GLYC

Amgen Inc (Score +39)

Sat Aug 02 19:05:23 UTC 2025

US Large Caps: Amgen Inc has a total score of +39

The score is composed from the following sections:

• +29 Price
• 0 Sentiment
• +4 Fundamentals
• 0 Flow
• +6 Models

https://dev.darwinknows.com/assets/AMGN.XNGS
#DarwinKnows #Amgen #AMGN $AMGN

Athira Pharma Inc (Score -4)

Sat Aug 02 19:05:20 UTC 2025

US Stocks: Athira Pharma Inc has an overall score of -4

The score is composed from the following sections:

• +21 Price
• 0 Sentiment
• +1 Fundamentals
• -9 Flow
• -17 Models

https://dev.darwinknows.com/assets/ATHA.XNCM
#DarwinKnows #AthiraPharma #ATHA $ATHA

Asset Analysis

Sat Aug 02 18:03:04 UTC 2025

Here are the analyser results for these 138 assets.

Best Score	Merck & Co Inc (MRK) with a score of +43
Worst Score	GlycoMimetics Inc (GLYC) with a score of -64
Best 1 day performer	Plus Therapeutics Inc (PSTV) with a 1 day return of +22.9%.
Worst 1 day performer	GlycoMimetics Inc (GLYC) with a 200 day return of -99.1%.
Top 200 day performer	Abivax SA (ABVX) with a 200 day return of +563.8%.
Bottom 200 day performer	NewGenIvf Group Ltd (NIVF) with a 200 day return of -99.8%.
Highest 5 day RSI	Arecor Therapeutics PLC (AREC) with a 5 day RSI of 100.0.
Lowest 5 day RSI	Alzamend Neuro Inc (ALZN) with a 5 day RSI of 0.88.
Most active	Healthcare Triangle Inc (HCTI) with volume rel to 20 day average of 19.28x.

Regeneron Pharmaceuticals Inc (Score +6)

Sat Aug 02 18:00:41 UTC 2025

US Stocks: Regeneron Pharmaceuticals Inc has a total score of +6

The score is composed from the following sections:

• +5 Price
• 0 Sentiment
• +3 Fundamentals
• -2 Flow
• 0 Models

https://dev.darwinknows.com/assets/REGN.XNGS
#DarwinKnows #RegeneronPharmaceuticals #REGN $REGN

Innate Pharma SA (Valuation - Very Expensive)

Sat Aug 02 18:00:31 UTC 2025

Innate Pharma SA has the worst Darwin score in France. Innate Pharma SA has a total darwin score of -15

The valuation ratios for Innate Pharma SA present a troubling picture. The Enterprise Value to EBITDA ratio is -9.783, which is significantly worse than the peer average of -0.396, indicating that the market is valuing the company unfavorably compared to its earnings potential. The Price to Sales ratio stands at 6.989, while the peer average is 22.834, suggesting that the stock is overvalued relative to its sales. Furthermore, the earnings per share is negative at -0.610, contrasting sharply with the peer average of 0.345. Given these metrics, the company appears to be 'very expensive' as it struggles to generate profits and maintain a favorable valuation compared to its peers.

https://dev.darwinknows.com/assets/IPH.XPAR
#DarwinKnows #InnatePharma #IPH $IPH.FR

GlycoMimetics Inc (Overall - Unfavourable)

Sat Aug 02 18:00:29 UTC 2025

GlycoMimetics Inc has the worst Darwin score in United States. GlycoMimetics Inc has a total score of -64

The overall assessment of GlycoMimetics Inc is "unfavourable." The combination of unhealthy operational metrics, very expensive valuation ratios, neutral price sentiment, and positive model forecasts paints a concerning picture for potential investors. The negative earnings per share and profit margins indicate significant challenges in operational efficiency and profitability. While the positive outlook from the models suggests potential for price appreciation, the high valuation raises concerns about the sustainability of such growth. Investors should approach this asset with caution, as the risks appear to outweigh the potential rewards at this time.

https://dev.darwinknows.com/assets/GLYC.XNCM
#DarwinKnows #GlycoMimetics #GLYC $GLYC

Amgen Inc (Score +39)

Sat Aug 02 18:00:26 UTC 2025

US Large Caps: Amgen Inc has a total darwin score of +39

The score is composed from the following sections:

• +29 Price
• 0 Sentiment
• +4 Fundamentals
• 0 Flow
• +6 Models

https://dev.darwinknows.com/assets/AMGN.XNGS
#DarwinKnows #Amgen #AMGN $AMGN

Athira Pharma Inc (Score -4)

Sat Aug 02 18:00:23 UTC 2025

US Stocks: Athira Pharma Inc has an overall darwin score of -4

The score is composed from the following sections:

• +21 Price
• 0 Sentiment
• +1 Fundamentals
• -9 Flow
• -17 Models

https://dev.darwinknows.com/assets/ATHA.XNCM
#DarwinKnows #AthiraPharma #ATHA $ATHA

Alerts

Sat Aug 02 16:58:06 UTC 2025

Regeneron Pharmaceuticals Inc (Score +6)

Sat Aug 02 16:56:40 UTC 2025

US Stocks: Regeneron Pharmaceuticals Inc has an overall darwin score of +6

The score is composed from the following sections:

• +5 Price
• 0 Sentiment
• +3 Fundamentals
• -2 Flow
• 0 Models

https://dev.darwinknows.com/assets/REGN.XNGS
#DarwinKnows #RegeneronPharmaceuticals #REGN $REGN

Innate Pharma SA (Valuation - Very Expensive)

Sat Aug 02 16:56:31 UTC 2025

Innate Pharma SA has the worst Darwin score in France. Innate Pharma SA has an overall score of -15

The valuation ratios for Innate Pharma SA present a troubling picture. The Enterprise Value to EBITDA ratio is -9.783, which is significantly worse than the peer average of -0.396, indicating that the market is valuing the company unfavorably compared to its earnings potential. The Price to Sales ratio stands at 6.989, while the peer average is 22.834, suggesting that the stock is overvalued relative to its sales. Furthermore, the earnings per share is negative at -0.610, contrasting sharply with the peer average of 0.345. Given these metrics, the company appears to be 'very expensive' as it struggles to generate profits and maintain a favorable valuation compared to its peers.

https://dev.darwinknows.com/assets/IPH.XPAR
#DarwinKnows #InnatePharma #IPH $IPH.FR

GlycoMimetics Inc (Overall - Unfavourable)

Sat Aug 02 16:56:29 UTC 2025

GlycoMimetics Inc has the worst Darwin score in United States. GlycoMimetics Inc has an overall score of -64

The overall assessment of GlycoMimetics Inc is "unfavourable." The combination of unhealthy operational metrics, very expensive valuation ratios, neutral price sentiment, and positive model forecasts paints a concerning picture for potential investors. The negative earnings per share and profit margins indicate significant challenges in operational efficiency and profitability. While the positive outlook from the models suggests potential for price appreciation, the high valuation raises concerns about the sustainability of such growth. Investors should approach this asset with caution, as the risks appear to outweigh the potential rewards at this time.

https://dev.darwinknows.com/assets/GLYC.XNCM
#DarwinKnows #GlycoMimetics #GLYC $GLYC

Amgen Inc (Score +39)

Sat Aug 02 16:56:26 UTC 2025

US Large Caps: Amgen Inc has a total score of +39

The score is composed from the following sections:

• +29 Price
• 0 Sentiment
• +4 Fundamentals
• 0 Flow
• +6 Models

https://dev.darwinknows.com/assets/AMGN.XNGS
#DarwinKnows #Amgen #AMGN $AMGN

Athira Pharma Inc (Score -4)

Sat Aug 02 16:56:24 UTC 2025

US Stocks: Athira Pharma Inc has an overall darwin score of -4

The score is composed from the following sections:

• +21 Price
• 0 Sentiment
• +1 Fundamentals
• -9 Flow
• -17 Models

https://dev.darwinknows.com/assets/ATHA.XNCM
#DarwinKnows #AthiraPharma #ATHA $ATHA

Overbought Assets

Sat Aug 02 15:54:43 UTC 2025

Asset Name	RSI(10d)	Asset Score
Arecor Therapeutics PLC (AREC)	100.0	+4
Surgical Innovations Group PLC (SUN)	99.8	-2
Regis Healthcare Ltd (REG)	93.9	+21
Cleanspace Holdings Ltd (CSX)	87.3	-12
Bavarian Nordic A/S (BAVA)	84.0	-11
Abivax SA (ABVX)	83.8	+11
Eyenovia Inc (EYEN)	72.7	+15
Resmed Inc (RMD)	70.9	+20

Regeneron Pharmaceuticals Inc (Score +6)

Sat Aug 02 15:53:32 UTC 2025

US Stocks: Regeneron Pharmaceuticals Inc has a total darwin score of +6

The score is composed from the following sections:

• +5 Price
• 0 Sentiment
• +3 Fundamentals
• -2 Flow
• 0 Models

https://dev.darwinknows.com/assets/REGN.XNGS
#DarwinKnows #RegeneronPharmaceuticals #REGN $REGN

Innate Pharma SA (Valuation - Very Expensive)

Sat Aug 02 15:53:22 UTC 2025

Innate Pharma SA has the worst Darwin score in France. Innate Pharma SA has a total darwin score of -15

The valuation ratios for Innate Pharma SA present a troubling picture. The Enterprise Value to EBITDA ratio is -9.783, which is significantly worse than the peer average of -0.396, indicating that the market is valuing the company unfavorably compared to its earnings potential. The Price to Sales ratio stands at 6.989, while the peer average is 22.834, suggesting that the stock is overvalued relative to its sales. Furthermore, the earnings per share is negative at -0.610, contrasting sharply with the peer average of 0.345. Given these metrics, the company appears to be 'very expensive' as it struggles to generate profits and maintain a favorable valuation compared to its peers.

https://dev.darwinknows.com/assets/IPH.XPAR
#DarwinKnows #InnatePharma #IPH $IPH.FR

GlycoMimetics Inc (Overall - Unfavourable)

Sat Aug 02 15:53:20 UTC 2025

GlycoMimetics Inc has the worst Darwin score in United States. GlycoMimetics Inc has a total darwin score of -64

The overall assessment of GlycoMimetics Inc is "unfavourable." The combination of unhealthy operational metrics, very expensive valuation ratios, neutral price sentiment, and positive model forecasts paints a concerning picture for potential investors. The negative earnings per share and profit margins indicate significant challenges in operational efficiency and profitability. While the positive outlook from the models suggests potential for price appreciation, the high valuation raises concerns about the sustainability of such growth. Investors should approach this asset with caution, as the risks appear to outweigh the potential rewards at this time.

https://dev.darwinknows.com/assets/GLYC.XNCM
#DarwinKnows #GlycoMimetics #GLYC $GLYC

Amgen Inc (Score +39)

Sat Aug 02 15:53:16 UTC 2025

US Large Caps: Amgen Inc has an overall score of +39

The score is composed from the following sections:

• +29 Price
• 0 Sentiment
• +4 Fundamentals
• 0 Flow
• +6 Models

https://dev.darwinknows.com/assets/AMGN.XNGS
#DarwinKnows #Amgen #AMGN $AMGN

Athira Pharma Inc (Score -4)

Sat Aug 02 15:53:14 UTC 2025

US Stocks: Athira Pharma Inc has an overall score of -4

The score is composed from the following sections:

• +21 Price
• 0 Sentiment
• +1 Fundamentals
• -9 Flow
• -17 Models

https://dev.darwinknows.com/assets/ATHA.XNCM
#DarwinKnows #AthiraPharma #ATHA $ATHA

Oversold Assets

Sat Aug 02 14:51:36 UTC 2025

Asset Name	RSI(10d)	Asset Score
Opthea Ltd (OPT)	6.2	-13
Alzamend Neuro Inc (ALZN)	7.2	-21
Lyra Therapeutics Inc (LYRA)	10.6	+4
agilon health inc (AGL)	11.5	-27
Kiora Pharmaceuticals Inc (KPRX)	11.9	-14
Novo Nordisk A/S (NOVO-B)	12.0	0
PMGC Holdings Inc (ELAB)	12.3	-1
Demant A/S (DEMANT)	13.7	+12
NewGenIvf Group Ltd (NIVF)	13.8	0
Paradigm Biopharmaceuticals Ltd (PAR)	15.6	+13
Emergent BioSolutions Inc (EBS)	16.0	+14
DENTSPLY SIRONA Inc (XRAY)	16.2	-6
Epigenomics AG (ECX)	16.4	+7
Fresenius Medical Care AG (FME)	16.5	+5
Sonova Holding AG (SOON)	16.8	+10
Imugene Ltd (IMU)	17.0	-10
Ambu A/S (AMBU_B)	17.1	-25
Ecofibre Ltd (EOF)	18.0	-9
Straumann Holding AG (STMN)	18.1	+5
Sharps Technology Inc (STSS)	18.2	-2
Helius Medical Technologies Inc (HSDT)	19.3	-18
Conduit Pharmaceuticals Inc (CDT)	19.3	-10
InMed Pharmaceuticals Inc (INM)	19.5	-19
GN Store Nord A/S (GN)	19.7	-19
Doximity Inc (DOCS)	20.1	+17
PYC Therapeutics Ltd (PYC)	20.1	+27
Oragenics Inc (OGEN)	20.2	+5
Sagimet Biosciences Inc (SGMT)	22.0	+27
Bioventus Inc (BVS)	22.1	+15
Merck KGaA (MRK)	22.1	-2
Sartorius Stedim Biotech SA (DIM)	22.4	-8
Dermapharm Holding SE (DMP)	22.6	+17
Klotho Neurosciences Inc (KLTO)	22.7	+26
Illumina Inc (ILMN)	23.2	+3
Nuwellis Inc (NUWE)	23.3	-19
Telix Pharmaceuticals Ltd (TLX)	24.1	+1
Zealand Pharma A/S (ZEAL)	24.2	-7
Prestige Consumer Healthcare Inc (PBH)	24.2	+4
Healthequity Inc (HQY)	26.4	+18
Coloplast A/S (COLO_B)	26.6	-5
Medical Developments International Ltd (MVP)	26.7	+19
Agenus Inc (AGEN)	27.8	+28
Intuitive Surgical Inc (ISRG)	28.0	+20
Henry Schein Inc (HSIC)	28.3	-3
Hikma Pharmaceuticals PLC (HIK)	28.5	-1
Revelation Biosciences Inc (REVB)	28.7	-8
ConvaTec Group PLC (CTEC)	29.0	+15
Clearside Biomedical Inc (CLSD)	29.4	+13
Bluejay Diagnostics Inc (BJDX)	29.4	-8
Genmab A/S (GMAB)	29.6	-9

Regeneron Pharmaceuticals Inc (Score +6)

Sat Aug 02 14:50:22 UTC 2025

US Stocks: Regeneron Pharmaceuticals Inc has a total darwin score of +6

The score is composed from the following sections:

• +5 Price
• 0 Sentiment
• +3 Fundamentals
• -2 Flow
• 0 Models

https://dev.darwinknows.com/assets/REGN.XNGS
#DarwinKnows #RegeneronPharmaceuticals #REGN $REGN

Innate Pharma SA (Valuation - Very Expensive)

Sat Aug 02 14:50:12 UTC 2025

Innate Pharma SA has the worst Darwin score in France. Innate Pharma SA has a total darwin score of -15

The valuation ratios for Innate Pharma SA present a troubling picture. The Enterprise Value to EBITDA ratio is -9.783, which is significantly worse than the peer average of -0.396, indicating that the market is valuing the company unfavorably compared to its earnings potential. The Price to Sales ratio stands at 6.989, while the peer average is 22.834, suggesting that the stock is overvalued relative to its sales. Furthermore, the earnings per share is negative at -0.610, contrasting sharply with the peer average of 0.345. Given these metrics, the company appears to be 'very expensive' as it struggles to generate profits and maintain a favorable valuation compared to its peers.

https://dev.darwinknows.com/assets/IPH.XPAR
#DarwinKnows #InnatePharma #IPH $IPH.FR

GlycoMimetics Inc (Overall - Unfavourable)

Sat Aug 02 14:50:11 UTC 2025

GlycoMimetics Inc has the worst Darwin score in United States. GlycoMimetics Inc has an overall darwin score of -64

The overall assessment of GlycoMimetics Inc is "unfavourable." The combination of unhealthy operational metrics, very expensive valuation ratios, neutral price sentiment, and positive model forecasts paints a concerning picture for potential investors. The negative earnings per share and profit margins indicate significant challenges in operational efficiency and profitability. While the positive outlook from the models suggests potential for price appreciation, the high valuation raises concerns about the sustainability of such growth. Investors should approach this asset with caution, as the risks appear to outweigh the potential rewards at this time.

https://dev.darwinknows.com/assets/GLYC.XNCM
#DarwinKnows #GlycoMimetics #GLYC $GLYC

Amgen Inc (Score +39)

Sat Aug 02 14:50:07 UTC 2025

US Large Caps: Amgen Inc has a total darwin score of +39

The score is composed from the following sections:

• +29 Price
• 0 Sentiment
• +4 Fundamentals
• 0 Flow
• +6 Models

https://dev.darwinknows.com/assets/AMGN.XNGS
#DarwinKnows #Amgen #AMGN $AMGN

Athira Pharma Inc (Score -4)

Sat Aug 02 14:50:05 UTC 2025

US Stocks: Athira Pharma Inc has an overall darwin score of -4

The score is composed from the following sections:

• +21 Price
• 0 Sentiment
• +1 Fundamentals
• -9 Flow
• -17 Models

https://dev.darwinknows.com/assets/ATHA.XNCM
#DarwinKnows #AthiraPharma #ATHA $ATHA

Laggards by 1 Day Performance

Sat Aug 02 13:48:49 UTC 2025

Asset Name	Perf(1d)%	Asset Score
GlycoMimetics Inc (GLYC)	-99.1	-64
Healthcare Triangle Inc (HCTI)	-38.9	+3
Helius Medical Technologies Inc (HSDT)	-11.7	-18
Eyenovia Inc (EYEN)	-9.2	+15
Medical Developments International Ltd (MVP)	-9.0	+19
NewGenIvf Group Ltd (NIVF)	-8.0	0
Illumina Inc (ILMN)	-7.8	+3
Clearside Biomedical Inc (CLSD)	-7.8	+13
Basel Medical Group Ltd (BMGL)	-7.8	0
Imugene Ltd (IMU)	-7.4	-10
Cardiol Therapeutics Inc (CRDL)	-7.3	+13
Straumann Holding AG (STMN)	-7.2	+5
PMGC Holdings Inc (ELAB)	-6.7	-1
Healthequity Inc (HQY)	-6.1	+18
Hims & Hers Health Inc (HIMS)	-5.5	+8
Anteotech Ltd (ADO)	-5.3	+15
Bioventus Inc (BVS)	-5.2	+15
Nuwellis Inc (NUWE)	-5.2	-19
Traws Pharma Inc (TRAW)	-5.2	-22
Sagimet Biosciences Inc (SGMT)	-5.1	+27
agilon health inc (AGL)	-5.0	-27
Zealand Pharma A/S (ZEAL)	-4.7	-7
Klotho Neurosciences Inc (KLTO)	-4.6	+26
Ambu A/S (AMBU_B)	-4.5	-25
Nanosonics Ltd (NAN)	-4.4	+7
Abivax SA (ABVX)	-4.4	+11
Telix Pharmaceuticals Ltd (TLX)	-4.3	+1
Polynovo Ltd (PNV)	-4.3	-2
Emergent BioSolutions Inc (EBS)	-4.3	+14
Clinuvel Pharmaceuticals Ltd (CUV)	-4.2	-19
Pharming Group NV (PHARM)	-4.1	+7
Starpharma Holdings Ltd (SPL)	-4.0	-11
Uniphar PLC (UPR)	-3.9	+20
Genmab A/S (GMAB)	-3.5	-9

Regeneron Pharmaceuticals Inc (Score +6)

Sat Aug 02 13:47:35 UTC 2025

US Stocks: Regeneron Pharmaceuticals Inc has an overall darwin score of +6

The score is composed from the following sections:

• +5 Price
• 0 Sentiment
• +3 Fundamentals
• -2 Flow
• 0 Models

https://dev.darwinknows.com/assets/REGN.XNGS
#DarwinKnows #RegeneronPharmaceuticals #REGN $REGN

Innate Pharma SA (Valuation - Very Expensive)

Sat Aug 02 13:47:24 UTC 2025

Innate Pharma SA has the worst Darwin score in France. Innate Pharma SA has an overall score of -15

The valuation ratios for Innate Pharma SA present a troubling picture. The Enterprise Value to EBITDA ratio is -9.783, which is significantly worse than the peer average of -0.396, indicating that the market is valuing the company unfavorably compared to its earnings potential. The Price to Sales ratio stands at 6.989, while the peer average is 22.834, suggesting that the stock is overvalued relative to its sales. Furthermore, the earnings per share is negative at -0.610, contrasting sharply with the peer average of 0.345. Given these metrics, the company appears to be 'very expensive' as it struggles to generate profits and maintain a favorable valuation compared to its peers.

https://dev.darwinknows.com/assets/IPH.XPAR
#DarwinKnows #InnatePharma #IPH $IPH.FR

GlycoMimetics Inc (Overall - Unfavourable)

Sat Aug 02 13:47:23 UTC 2025

GlycoMimetics Inc has the worst Darwin score in United States. GlycoMimetics Inc has a total score of -64

The overall assessment of GlycoMimetics Inc is "unfavourable." The combination of unhealthy operational metrics, very expensive valuation ratios, neutral price sentiment, and positive model forecasts paints a concerning picture for potential investors. The negative earnings per share and profit margins indicate significant challenges in operational efficiency and profitability. While the positive outlook from the models suggests potential for price appreciation, the high valuation raises concerns about the sustainability of such growth. Investors should approach this asset with caution, as the risks appear to outweigh the potential rewards at this time.

https://dev.darwinknows.com/assets/GLYC.XNCM
#DarwinKnows #GlycoMimetics #GLYC $GLYC

Amgen Inc (Score +39)

Sat Aug 02 13:47:19 UTC 2025

US Large Caps: Amgen Inc has a total darwin score of +39

The score is composed from the following sections:

• +29 Price
• 0 Sentiment
• +4 Fundamentals
• 0 Flow
• +6 Models

https://dev.darwinknows.com/assets/AMGN.XNGS
#DarwinKnows #Amgen #AMGN $AMGN

Athira Pharma Inc (Score -4)

Sat Aug 02 13:47:16 UTC 2025

US Stocks: Athira Pharma Inc has an overall score of -4

The score is composed from the following sections:

• +21 Price
• 0 Sentiment
• +1 Fundamentals
• -9 Flow
• -17 Models

https://dev.darwinknows.com/assets/ATHA.XNCM
#DarwinKnows #AthiraPharma #ATHA $ATHA

Leaders by 1 Day Performance

Sat Aug 02 12:45:44 UTC 2025

Asset Name	Perf(1d)%	Asset Score
Plus Therapeutics Inc (PSTV)	22.9	-8
Cannara Biotech Inc (LOVE)	6.8	-1
Physiomics PLC (PYC)	5.7	-3
MoonLake Immunotherapeutics (MLTX)	4.9	+15
Alcidion Group Ltd (ALC)	4.3	+17
Innovotech Inc (IOT)	4.2	+12
Tempest Therapeutics Inc (TPST)	3.6	-16
Biogen Inc (BIIB)	3.1	-8
Resmed Inc (RMD)	2.7	+20
Imunon Inc (IMNN)	2.5	-7
Regeneron Pharmaceuticals Inc (REGN)	2.5	+6
Mayne Pharma Group Ltd (MYX)	2.4	-2
Sanofi SA (SAN)	1.9	+4
Haleon PLC (HLN)	1.6	+21
Johnson & Johnson (JNJ)	1.6	+35
Merck & Co Inc (MRK)	1.5	+43
PolyPid Ltd (PYPD)	1.5	+6
Kronos Bio Inc (KRON)	1.5	+8
Vertex Pharmaceuticals Inc (VRTX)	1.2	+7
Conduit Pharmaceuticals Inc (CDT)	1.1	-10
Sharps Technology Inc (STSS)	1.0	-2
Regis Healthcare Ltd (REG)	1.0	+21
Incyte Corp (INCY)	0.9	0
Arecor Therapeutics PLC (AREC)	0.9	+4
Gilead Sciences Inc (GILD)	0.8	+29
Cleanspace Holdings Ltd (CSX)	0.7	-12
Pharvaris NV (PHVS)	0.6	+22
Amgen Inc (AMGN)	0.6	+39
CVS Health Corp (CVS)	0.6	+31
BioMarin Pharmaceutical Inc (BMRN)	0.5	-17
Henry Schein Inc (HSIC)	0.5	-3
Intuitive Surgical Inc (ISRG)	0.4	+20
Integral Diagnostics Ltd (IDX)	0.4	+21
Bio-Techne Corp (TECH)	0.3	-10

Regeneron Pharmaceuticals Inc (Score +6)

Sat Aug 02 12:44:21 UTC 2025

US Stocks: Regeneron Pharmaceuticals Inc has a total score of +6

The score is composed from the following sections:

• +5 Price
• 0 Sentiment
• +3 Fundamentals
• -2 Flow
• 0 Models

https://dev.darwinknows.com/assets/REGN.XNGS
#DarwinKnows #RegeneronPharmaceuticals #REGN $REGN

Innate Pharma SA (Valuation - Very Expensive)

Sat Aug 02 12:44:10 UTC 2025

Innate Pharma SA has the worst Darwin score in France. Innate Pharma SA has a total darwin score of -15

The valuation ratios for Innate Pharma SA present a troubling picture. The Enterprise Value to EBITDA ratio is -9.783, which is significantly worse than the peer average of -0.396, indicating that the market is valuing the company unfavorably compared to its earnings potential. The Price to Sales ratio stands at 6.989, while the peer average is 22.834, suggesting that the stock is overvalued relative to its sales. Furthermore, the earnings per share is negative at -0.610, contrasting sharply with the peer average of 0.345. Given these metrics, the company appears to be 'very expensive' as it struggles to generate profits and maintain a favorable valuation compared to its peers.

https://dev.darwinknows.com/assets/IPH.XPAR
#DarwinKnows #InnatePharma #IPH $IPH.FR

GlycoMimetics Inc (Overall - Unfavourable)

Sat Aug 02 12:44:09 UTC 2025

GlycoMimetics Inc has the worst Darwin score in United States. GlycoMimetics Inc has an overall darwin score of -64

The overall assessment of GlycoMimetics Inc is "unfavourable." The combination of unhealthy operational metrics, very expensive valuation ratios, neutral price sentiment, and positive model forecasts paints a concerning picture for potential investors. The negative earnings per share and profit margins indicate significant challenges in operational efficiency and profitability. While the positive outlook from the models suggests potential for price appreciation, the high valuation raises concerns about the sustainability of such growth. Investors should approach this asset with caution, as the risks appear to outweigh the potential rewards at this time.

https://dev.darwinknows.com/assets/GLYC.XNCM
#DarwinKnows #GlycoMimetics #GLYC $GLYC

Amgen Inc (Score +39)

Sat Aug 02 12:44:05 UTC 2025

US Large Caps: Amgen Inc has an overall score of +39

The score is composed from the following sections:

• +29 Price
• 0 Sentiment
• +4 Fundamentals
• 0 Flow
• +6 Models

https://dev.darwinknows.com/assets/AMGN.XNGS
#DarwinKnows #Amgen #AMGN $AMGN

Athira Pharma Inc (Score -4)

Sat Aug 02 12:44:03 UTC 2025

US Stocks: Athira Pharma Inc has an overall score of -4

The score is composed from the following sections:

• +21 Price
• 0 Sentiment
• +1 Fundamentals
• -9 Flow
• -17 Models

https://dev.darwinknows.com/assets/ATHA.XNCM
#DarwinKnows #AthiraPharma #ATHA $ATHA

Relative Scores

Sat Aug 02 11:41:54 UTC 2025

The average score across these 138 assets is 4.0.

The relative categorisation of these assets is as follows:

Category	Score Range	#	Assets
Strongest	21.6 to 43.0	19	Pharvaris NV (PHVS) +22, ICON PLC (ICLR) +24, Ansell Ltd (ANN) +26, Novartis AG (NOVN) +26, Klotho Neurosciences Inc (KLTO) +26, PYC Therapeutics Ltd (PYC) +27, Sagimet Biosciences Inc (SGMT) +27, BTC Health Ltd (BTC) +27, Agenus Inc (AGEN) +28, Sonic Healthcare Ltd (SHL) +29, Gilead Sciences Inc (GILD) +29, EssilorLuxottica SA (EL) +29, Biomerieux SA (BIM) +31, CVS Health Corp (CVS) +31, Cochlear Ltd (COH) +32, Johnson & Johnson (JNJ) +35, Pro Medicus Ltd (PME) +36, Amgen Inc (AMGN) +39, Merck & Co Inc (MRK) +43
Above Average	0.2 to 21.6	57	Telix Pharmaceuticals Ltd (TLX) +1, Aspen Pharmacare Holdings Ltd (APN) +1, Ramsay Health Care Ltd (RHC) +3, Illumina Inc (ILMN) +3, Healthcare Triangle Inc (HCTI) +3, Prestige Consumer Healthcare Inc (PBH) +4, Sanofi SA (SAN) +4, Arecor Therapeutics PLC (AREC) +4, Lyra Therapeutics Inc (LYRA) +4, Fresenius Medical Care AG (FME) +5, Straumann Holding AG (STMN) +5, Oragenics Inc (OGEN) +5, Regeneron Pharmaceuticals Inc (REGN) +6, Koninklijke Philips NV (PHIA) +6, PolyPid Ltd (PYPD) +6, Nanosonics Ltd (NAN) +7, Epigenomics AG (ECX) +7, Vertex Pharmaceuticals Inc (VRTX) +7, Argenica Therapeutics Ltd (AGN) +7, Pharming Group NV (PHARM) +7, Charles River Laboratories International Inc (CRL) +8, Hims & Hers Health Inc (HIMS) +8, Kronos Bio Inc (KRON) +8, Lonza Group AG (LONN) +9, Concentra Group Holdings Parent Inc (CON) +10, Sonova Holding AG (SOON) +10, Turnstone Biologics Corp (TSBX) +10, Abivax SA (ABVX) +11, Evotec SE (EVT) +12, CSL Ltd (CSL) +12, Demant A/S (DEMANT) +12, Innovotech Inc (IOT) +12, Paradigm Biopharmaceuticals Ltd (PAR) +13, Cardiol Therapeutics Inc (CRDL) +13, Clearside Biomedical Inc (CLSD) +13, GSK plc (GSK) +14, Emergent BioSolutions Inc (EBS) +14, Anteotech Ltd (ADO) +15, Bioventus Inc (BVS) +15, Shield Therapeutics PLC (STX) +15, ConvaTec Group PLC (CTEC) +15, Eyenovia Inc (EYEN) +15, MoonLake Immunotherapeutics (MLTX) +15, Sigma Healthcare Ltd (SIG) +16, Alcidion Group Ltd (ALC) +17, Dermapharm Holding SE (DMP) +17, Doximity Inc (DOCS) +17, Healthequity Inc (HQY) +18, Medical Developments International Ltd (MVP) +19, Resmed Inc (RMD) +20, Intuitive Surgical Inc (ISRG) +20, Uniphar PLC (UPR) +20, Phio Pharmaceuticals Corp (PHIO) +20, Regis Healthcare Ltd (REG) +21, Integral Diagnostics Ltd (IDX) +21, Smith & Nephew PLC (SN.) +21, Haleon PLC (HLN) +21
Average	-21.2 to 0.2	56	Alzamend Neuro Inc (ALZN) -21, Clinuvel Pharmaceuticals Ltd (CUV) -19, GN Store Nord A/S (GN) -19, InMed Pharmaceuticals Inc (INM) -19, Cellectar Biosciences Inc (CLRB) -19, Nuwellis Inc (NUWE) -19, Helius Medical Technologies Inc (HSDT) -18, BioMarin Pharmaceutical Inc (BMRN) -17, Geratherm Medical AG (GME) -17, Alcon AG (ALC) -16, Tempest Therapeutics Inc (TPST) -16, Innate Pharma SA (IPH) -15, Advanced Medical Solutions Group PLC (AMS) -15, Kiora Pharmaceuticals Inc (KPRX) -14, Opthea Ltd (OPT) -13, Cleanspace Holdings Ltd (CSX) -12, Starpharma Holdings Ltd (SPL) -11, Bavarian Nordic A/S (BAVA) -11, Imugene Ltd (IMU) -10, Bio-Techne Corp (TECH) -10, Conduit Pharmaceuticals Inc (CDT) -10, Ecofibre Ltd (EOF) -9, Genmab A/S (GMAB) -9, Mesoblast Ltd (MSB) -8, Biogen Inc (BIIB) -8, Sartorius Stedim Biotech SA (DIM) -8, Plus Therapeutics Inc (PSTV) -8, Revelation Biosciences Inc (REVB) -8, Bluejay Diagnostics Inc (BJDX) -8, Zealand Pharma A/S (ZEAL) -7, Imunon Inc (IMNN) -7, Pacific Smiles Group Ltd (PSQ) -6, DENTSPLY SIRONA Inc (XRAY) -6, AstraZeneca PLC (AZN) -5, Coloplast A/S (COLO_B) -5, Athira Pharma Inc (ATHA) -4, Physiomics PLC (PYC) -3, Henry Schein Inc (HSIC) -3, Roche Holding AG (ROG) -3, Roche Holding AG (RO) -3, Surgical Innovations Group PLC (SUN) -2, Siemens Healthineers AG (SHL) -2, Polynovo Ltd (PNV) -2, Mayne Pharma Group Ltd (MYX) -2, Merck KGaA (MRK) -2, Sharps Technology Inc (STSS) -2, 60 Degrees Pharmaceuticals Inc (SXTP) -2, Humana Inc (HUM) -1, Hikma Pharmaceuticals PLC (HIK) -1, Cannara Biotech Inc (LOVE) -1, PMGC Holdings Inc (ELAB) -1, Race Oncology Ltd (RAC) 0, Incyte Corp (INCY) 0, NewGenIvf Group Ltd (NIVF) 0, Basel Medical Group Ltd (BMGL) 0, Novo Nordisk A/S (NOVO-B) 0
Below Average	-42.6 to -21.2	5	Angle PLC (AGL) -29, Healius Ltd (HLS) -28, agilon health inc (AGL) -27, Ambu A/S (AMBU_B) -25, Traws Pharma Inc (TRAW) -22
Weakest	-64.0 to -42.6	1	GlycoMimetics Inc (GLYC) -64